COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment …

H Abdel-Razeq, B Sharaf, MJ Al-Jaghbeer… - Journal of Thrombosis …, 2023 - Springer
Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …
被引用次数：7 相关文章

COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment …

H Abdel-Razeq, B Sharaf, MJ Al-Jaghbeer… - … of Thrombosis and …, 2023 - europepmc.org
Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …

COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment …

H Abdel-Razeq, MJ Al-Jaghbeer… - … of thrombosis and …, 2023 - pubmed.ncbi.nlm.nih.gov
Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk
assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to …

[引用][C] COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active …

H Abdel-Razeq, MJ Baha'Sharaf, H Abu-Fares… - Journal of Thrombosis …, 2023 - cir.nii.ac.jp
COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic
events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or …